Merck has launched a Phase 3 trial for subcutaneous pembrolizumab combined with berahyaluronidase alfa, achieving its primary goals.

Otsuka shared new information about Sibeprenlimab, an experimental monoclonal antibody aimed at treating IgA nephropathy in adults.

Nurix Therapeutics showcases early data on two programs for autoimmune and inflammatory diseases, NX-5948 and GS-6791, at ACR Convergence 2024.

Fate Therapeutics Showcases FT522, an Off-the-Shelf, ADR-Equipped CAR NK Cell Candidate, at the 2024 ACR Convergence.

Allogene Therapeutics shares preclinical findings for ALLO-329, a dual CAR T targeting CD19 and CD70, aimed at treating autoimmune diseases.

Ustekinumab, also known by its brand name Stelara, is a groundbreaking drug targeting interleukin-12 (IL-12) and interleukin-23 (IL-23).

Lilly's tirzepatide lowered the chance of worsening heart failure events by 38% in adults who have HFpEF and obesity.

Plozasiran, a novel therapeutic agent, is a small interfering RNA (siRNA) developed by Silence Therapeutics.

AbelZeta showcases preliminary findings on C-CAR168 for autoimmune disease treatment at ACR Convergence 2024.

Sacituzumab govitecan-hziy, also known as Trodelvy, is an antibody-drug conjugate (ADC) developed by Immunomedics, now part of Gilead Sciences.

Rona Therapeutics showcased encouraging Phase 1 findings for RN0191, an innovative siRNA treatment aimed at PCSK9, during the 2024 AHA Scientific Sessions.

The global pain management market was valued at $79.4 billion in 2021 and is projected to grow to $120.7 billion by 2027, with a compound annual growth rate (CAGR) of 7.39%.